Stanley B Kaye
Overview
Explore the profile of Stanley B Kaye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
2216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dolly S, Migali C, Tunariu N, Della-Pepa C, Khakoo S, Hazell S, et al.
ESMO Open
. 2017 Aug;
2(1):e000101.
PMID: 28761723
Conclusion: These case presentations highlight a subgroup of rare MPeM that behave indolently that is compatible with long-term survival. This series identifies the use of targeted therapies with PI3K-mTOR-based inhibitors...
2.
Ang J, Pal A, Asad Y, Henley A, Valenti M, Box G, et al.
Mol Cancer Ther
. 2017 Jun;
16(10):2315-2323.
PMID: 28637716
MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based metabolomics, we...
3.
Bolton K, Tyrer J, Song H, Ramus S, Notaridou M, Jones C, et al.
Nat Genet
. 2015 Dec;
48(1):101.
PMID: 26711112
No abstract available.
4.
Tan D, Kaye S
Am Soc Clin Oncol Educ Book
. 2015 May;
:114-21.
PMID: 25993149
Retrospective studies have shown an improved prognosis, higher response rates to platinum-containing regimens, and longer treatment-free intervals between relapses in patients with BRCA 1 and BRCA 2 (BRCA1/2)-mutated ovarian cancer...
5.
Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, et al.
Clin Cancer Res
. 2015 Feb;
21(8):1869-76.
PMID: 25649020
Purpose: Novel antitumor therapies against the PI3K-AKT-mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents...
6.
Syrios J, Banerjee S, Kaye S
Anticancer Res
. 2014 Apr;
34(5):2069-77.
PMID: 24778008
Ovarian cancer is the most frequent cause of death from gynaecological malignancy in the Western countries, and differences in outcome among different histological subtypes are being increasingly recognized. It is...
7.
Charbonneau B, Moysich K, Kalli K, Oberg A, Vierkant R, Fogarty Z, et al.
Cancer Immunol Res
. 2014 Apr;
2(4):332-40.
PMID: 24764580
The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations...
8.
Block M, Charbonneau B, Vierkant R, Fogarty Z, Bamlet W, Pharoah P, et al.
Cancer Epidemiol Biomarkers Prev
. 2014 Apr;
23(7):1421-7.
PMID: 24740199
Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear...
9.
Charbonneau B, Block M, Bamlet W, Vierkant R, Kalli K, Fogarty Z, et al.
Cancer Res
. 2013 Nov;
74(3):852-61.
PMID: 24272484
A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of...
10.
Monk B, Kaye S, Poveda A, Herzog T, Aracil M, Nieto A, et al.
Gynecol Oncol
. 2013 Nov;
132(1):176-80.
PMID: 24211400
Objective: This study investigated the relationship between 13 proteins involved in DNA damage and the outcomes of patients with recurrent ovarian cancer (ROC). Patients And Methods: Immunohistochemistry staining was performed...